Ann: PD1-Vaxx Presentation at ESMO Congress 2021 Annual Meeting, page-4

The study has fully enrolled into the third dose cohort, each cohort includes3 patients. Treatment comprises 3 primary injections (days, 1, 15 and 29), aday 64 vaccination and from there a maintenance treatment every 2 months(see Figure 4). No dose limiting toxicity, or any significant vaccination relatedadverse event have been reported. Minor, grade 1 injection site reactionwere reported with a duration of 1 day.

Overall, the treatment is well tolerated, and the study will therefore moveinto the expansion cohort enrolling 10 patients into the optimal biologicaldose, to confirm safety response and the development of PD1-antibody incorrelation to response.